Metabolic diseases drug discovery world summit

Expert Opinion on Investigational Drugs

Volumn 12, Issue 10, 2003, Pages 1721-1726

  Sarabu, Ramkanth ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

5 HT2C agonists; CCK A agonists; DPP IV inhibitors; Exenatide; Glucocorticoid receptor antagonist; Glucokinase activators; PDHK inhibitors; PTP1B ASO; PTP1B inhibitors

Indexed keywords

6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; A 348441; ANTIOBESITY AGENT; ANTISENSE OLIGONUCLEOTIDE; AZD 7545; CANNABINOID RECEPTOR AGONIST; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CP 86753401; DICHLOROACETIC ACID; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME ACTIVATOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN; OXIDOREDUCTASE INHIBITOR; PEPTIDE HYDROLASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PYRUVATE DEHYDROGENASE; RETINOID X RECEPTOR; RO 281675; ROSIGLITAZONE; SEROTONIN 2C AGONIST; SULFONYLUREA; SYNTHETIC PEPTIDE; THIAZOLIDINE DERIVATIVE; THYROTROPIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ANIMAL; ARTICLE; CELL ASSAY; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD INTAKE; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION; SYMPOSIUM;

ANIMALS; DIABETES MELLITUS; HUMANS; OBESITY;

EID: 0142148217     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.10.1721     Document Type: Article

References (10)

1. LIU G, XIN Z, LIANG H et al.: Selective protein tyrosine phosphatase 1b inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J. Med. Chem. (2003) 46(16):3437-3440.
2. LIU G, XIN Z, PIE Z et al.: Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J. Med. Chem. (2003) (In press).
3. ZINKER BA, RONDINONE CM, TREVILLYAN JM et al.: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA (2002) 99(17):11357-11362.
4. GIANNOUKAKIS N: Exenatide. Amylin/Eli Lilly. Curr. Opin. Investig. Drugs (2003) 4(4):459-465.
5. VILLHAUER EB, BRINKMAN J, NADERI GB et al.: 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. (2003) 46(13):2774-2789.
6. BEBERNITZ GR, AICHER TD, STANTON JL et al.: Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J . Med. Chem. (2000) 43(11):2248-2257.
7. GRIMSBY J, SARABU R, CORBETT WL et al.: Allosteric activators of glucokinase: potential role in diabetes therapy. Science (2003) 301:370-373.
8. GANTZ I, FONG TM: The melanocortin system. Am. J. Physiol. Endocrinol. Metab. (2003) 284:E468-E474.
9. HIRST GC, AQUINO C, BIRKEMO L: Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II):u optimization of the C3 amino substituent. J. Med. Chem. (1996) 39(26):5236-5245.
10. CLARK RV et al. ENDO 2002 - 84th Annual Meeting of Endocrine Society, San Francisco, FL, USA (2002) (Abstract P3-441).